Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $640,000.00 in Stock

Key Points

• Regeneron director Huda Zoghbi sold 800 shares at an average price of $800, generating $640,000 in proceeds. The Rule 10b5-1 transaction reduced her direct ownership by 31.96% to 1,703 shares.
• Regeneron reported a strong quarter, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year.
• The company declared a quarterly dividend of $0.94 per share, equivalent to a 0.5% yield, while analysts maintained an overall “Moderate Buy” rating with an average price target of $797.75.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Huda Zoghbi sold 800 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $0.99 on Wednesday, hitting $797.99. The company had a trading volume of 571,786 shares, compared to its average volume of 859,210. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market cap of $82.16 billion, a PE ratio of 19.72, a PEG ratio of 1.37 and a beta of 0.22. The business has a 50-day simple moving average of $665.31 and a 200-day simple moving average of $713.04.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.81 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Eylea HD and Dupixent franchises continue to support growth, while oncology products and pipeline progress provide additional catalysts. The company’s shares were described as having risen 21.9% over the past month. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s outlook despite recent clinical and legal concerns. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Multiple law firms repeated notices that investors have until September 14, 2026 to seek lead-plaintiff status in a securities class action. The announcements largely repeat the same lawsuit rather than disclose a new company development. Regeneron Class Action Lawsuit Notice
• Negative Sentiment: The litigation stems from allegations that Regeneron misled investors about the viability of its Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial’s failure reportedly erased approximately $11 billion in market value, increasing legal and reputational risk. REGN Stockholders Class Action Notice

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a report on Thursday, April 30th. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $797.75.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company's stock worth $7,004,838,000 after acquiring an additional 26,884 shares in the last quarter. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company's stock worth $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the period. Finally, Nuveen LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source